Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics

  • Gilead has thus far shown little inclination to develop its onco portfolio.
  • However, the onco space is one that can offer a good replacement option for its HCV franchise.
  • This article discusses how the CAR-T in solid tumor space can be one acquisition idea.

By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF-Paris

In an earlier article I discussed Gilead’s (GILD) directionless onco-heme pipeline, and showed that the pipeline as it is now will never be able to replace its antiviral product assets.

The full post is available to investor members only. Subscribe here.